Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study
Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a M4 positive allosteric modulator.
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise, with potential best-in-class pharmacology.
No convulsions were observed in pre-clinical studies conducted in multiple species, including rabbits.
Neumora plans to provide a comprehensive M4 franchise update by mid-2026.
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development.
Author's summary: Neumora starts Phase 1 study of NMRA-898.
More News
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Canada's youth facing growing opioid crisis: Calls for urgent action
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Meralco profit jumps 14% to P40 billion in 9 months
- D&H Distributing’s Advanced Solutions Plus Unit To Focus On The Enterprise, ‘A Pivotal Evolution’ For Its Business
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado